CAPIO BIOSCIENCES

Capio Biosciences is a biotech company focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. Capio Biosciences is developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.